Search

Antonella Converso

from Elkins Park, PA
Age ~51
Get Report
Also known as:
Antonella Convers, Antonella D
Phone and address:
7937 Montgomery Ave, Melrose Park, PA 19027
(215) 559-4185
Connected to:
Alana M Converse, 78Alberto Convers, 76Alexander Converse, 52Alexandra K Converse, 31Allan D Converse, 65Andrea Conversano, 63Angelo Converso, 56Annie E Converse, 103Brandon D Converse, 39Cary R Converse, 35

Antonella Converso Phones & Addresses

  • 7937 Montgomery Ave, Elkins Park, PA 19027 (215) 559-4185
  • Philadelphia, PA
  • 2325 Myrtle Ave, San Diego, CA 92104
  • Encinitas, CA
  • Newark, DE
  • Rydal, PA
  • Montgomery, PA
  • 7937 Montgomery Ave, Elkins Park, PA 19027

Work

Company: Merck Feb 2011 Address: West Point, PA Position: Team lead, exploratory chemistry

Education

Degree: Postdoctoral Research Associate School / High School: The Scripps Research Institute 2004 to 2006 Specialities: Organic chemistry

Skills

Drug Discovery • Drug Development • Medicinal Chemistry • Drug Design • Organic Synthesis • Organic Chemistry • Synthetic Organic Chemistry • Hplc • Chemistry • Lead Change • Lc Ms • Life Sciences • Adme • Purification • Nmr • Biotechnology • Heterocyclic Chemistry • Parallel Synthesis • Nuclear Magnetic Resonance

Languages

English • Italian

Industries

Pharmaceuticals

Resumes

Resumes

Antonella Converso Photo 1

Director

View page
Location:
Collegeville, PA
Industry:
Pharmaceuticals
Work:
Merck - West Point, PA since Feb 2011
Team Lead, Exploratory Chemistry
The Scripps Research Institute Jan 2004 - Jan 2006
Postdoctoral Research Associate
The Scripps Research Institute 1998 - 2003
Graduate Student
ISIS pharmaceuticals Sep 1997 - Jun 1998
Chemist
Education:
The Scripps Research Institute 2004 - 2006
Postdoctoral Research Associate, Organic chemistry The Scripps Research Institute 1998 - 2003
Doctor of Philosophy (Ph.D.), Organic Chemistry Università degli Studi della Calabria 1992 - 1997
Laurea (B.Sc./M.Sc.), Chemistry
Skills:
Drug Discovery
Drug Development
Medicinal Chemistry
Drug Design
Organic Synthesis
Organic Chemistry
Synthetic Organic Chemistry
Hplc
Chemistry
Lead Change
Lc Ms
Life Sciences
Adme
Purification
Nmr
Biotechnology
Heterocyclic Chemistry
Parallel Synthesis
Nuclear Magnetic Resonance
Languages:
English
Italian

Publications

Us Patents

Ahcy Hydrolase Inhibitors For Treatment Of Hyper Homocysteinemia

View page
US Patent:
8629275, Jan 14, 2014
Filed:
Aug 31, 2009
Appl. No.:
13/060775
Inventors:
Antonella Converso - Elkins Park PA, US
Timothy J. Hartingh - Blue Bell PA, US
Mark E. Fraley - North Wales PA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 471/02
US Classification:
546113
Abstract:
The present invention is directed to AHCY inhibitors of formula (I): which are useful in the treatment of diseases characterized by high homocysteine levels, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases characterized by high homocysteine levels.

Ahcy Hydrolase Inhibitors For Treatment Of Hyper Homocysteinemia

View page
US Patent:
20100305135, Dec 2, 2010
Filed:
Feb 18, 2009
Appl. No.:
12/811911
Inventors:
Robert M. Garbaccio - Lansdale PA, US
Antonella Converso - Elkins Park PA, US
Mark E. Fraley - North Wales PA, US
Timothy J. Hartingh - Blue Bell PA, US
Assignee:
MERCK & CO., INC. - Rahway NJ
International Classification:
A61K 31/4985
C07D 487/04
A61P 25/28
A61P 9/00
A61P 25/18
A61P 9/12
A61P 25/00
US Classification:
514249, 544350
Abstract:
The present invention is directed to AHCY inhibitors of formula (I) which are useful in the treatment of diseases characterized by high homocysteine levels, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases characterized by high homocysteine levels.

Oxazolobenzimidazole Derivatives

View page
US Patent:
20110124661, May 26, 2011
Filed:
May 8, 2009
Appl. No.:
12/992439
Inventors:
Edward J. Brnardic - Lansdale PA, US
Antonella Converso - Elkins Park PA, US
Mark E. Fraley - North Wales PA, US
Robert M. Garbaccio - Lansdale PA, US
Shaei Y. Huang - Lansdale PA, US
International Classification:
A61K 31/497
C07D 413/14
C07D 491/147
C07D 401/14
A61K 31/4439
A61K 31/437
A61P 25/18
US Classification:
51425505, 5462717, 546 83, 544405, 514338, 514293
Abstract:
The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

Oxazolobenzimidazole Derivatives

View page
US Patent:
20110178117, Jul 21, 2011
Filed:
Sep 16, 2009
Appl. No.:
13/120930
Inventors:
Antonella Converso - Elkins Park PA, US
Timothy John Hartingh - Blue Bell PA, US
Sylwia Stachura - Lansdale PA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/437
C07D 498/04
A61K 31/424
C07D 401/14
A61K 31/454
C07D 498/14
A61P 25/18
US Classification:
514293, 548218, 514375, 546199, 514322, 546 83
Abstract:
The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

Pyridinone Derivatives As Selective Cytotoxic Agents Against Hiv Infected Cells

View page
US Patent:
20220242847, Aug 4, 2022
Filed:
May 18, 2020
Appl. No.:
17/611448
Inventors:
Antonella CONVERSO - West Point PA, US
Abdellatif EL MARROUNI - West Point PA, US
Ashley FORSTER - West Point PA, US
Jessica L. FRIE - West Point PA, US
David N. HUNTER - West Point PA, US
Cheng WANG - West Point PA, US
Deping WANG - West Point PA, US
- Rahway NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 401/06
C07D 401/14
A61K 45/06
A61K 31/506
A61P 31/18
Abstract:
The present disclosure is directed to pyridinone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).

Phenyl-Cyanoquinolinone Pde9 Inhibitors

View page
US Patent:
20180208557, Jul 26, 2018
Filed:
Jul 27, 2016
Appl. No.:
15/745845
Inventors:
- Rahway NJ, US
ANTONELLA CONVERSO - ELKINS PARK PA, US
KEVIN RODZINAK - VALDOSTA GA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 215/54
A61P 25/18
A61P 25/14
Abstract:
The present invention is directed to phenylcyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Quinoline Carboxamide And Quinoline Carbonitrile Derivatives As Mglur2-Negative Allosteric Modulators, Compositions, And Their Use

View page
US Patent:
20160158217, Jun 9, 2016
Filed:
Feb 18, 2016
Appl. No.:
15/047224
Inventors:
- Rahway NJ, US
Antonella Converso - Elkins Park PA, US
Pablo De Leon - Philadelphia PA, US
Barbara Hanney - Pennsburg PA, US
Timothy John Hartingh - Blue Bell PA, US
Jesse Josef Manikowski - Worcester PA, US
Peter J. Manley - Harleysville PA, US
Robert Meissner - Newton MA, US
Zhaoyang Meng - Lansdale PA, US
James J. Perkins - Churchville PA, US
Michael T. Rudd - Collegeville PA, US
Youheng Shu - Blue Bell PA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/47
A61K 31/541
A61K 31/506
A61K 31/496
A61K 31/4985
A61K 31/4709
A61K 31/5377
Abstract:
The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I)

Quinoline Carboxamide And Quinoline Carbonitrile Derivatives As Mglur2-Negative Allosteric Modulators, Compositions, And Their Use

View page
US Patent:
20160159744, Jun 9, 2016
Filed:
Feb 18, 2016
Appl. No.:
15/047213
Inventors:
- Rahway NJ, US
Antonella Converso - Elkins Park PA, US
Pablo De Leon - Philadelphia PA, US
Barbara Hanney - Pennsburg PA, US
Timothy John Hartingh - Blue Bell PA, US
Jesse Josef Manikowski - Worcester PA, US
Peter J. Manley - Harleysville PA, US
Robert Meissner - Newton MA, US
Zhaoyang Meng - Lansdale PA, US
James J. Perkins - Churchville PA, US
Michael T. Rudd - Collegeville PA, US
Youheng Shu - Blue Bell PA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 215/48
C07D 409/04
C07D 401/06
C07D 417/14
C07D 417/06
C07D 401/14
C07D 471/04
C07D 401/04
C07D 413/06
Abstract:
The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I)
Control profile
Antonella Converso from Elkins Park, PA, age ~51 Get Report